American Medical Companies are performing Gene therapy trials in Colombia.

https://www.bioaccessla.com/blog/2017/10/22/why-gene-therapy-companies-are-looking-at-colombia-for-their-clinical-trials

Libella Gene Therapeutics —a US-based company— recently chose Colombia to conduct a phase I clinical trial that could represent a breakthrough in the treatment of Alzheimer's disease (AD) using gene therapy. The approval of a gene therapy trial in Colombia takes 30-45 days from the date of submission to an ethics committee. This time may be shorter or longer depending on how fast the ethics committee at the health institution (aka research center) evaluates the study documents. This positions Colombia as one of the countries with the fastest approval time (and lowest cost) in Latin America for gene therapy research. 

Gene therapy offers the ability to permanently correct a disease at its most basic level, the genome, and could offer cures for many conditions that are considered incurable. Unlike traditional drugs, which tend to be taken for months or years at a time, gene therapy interventions are intended to be one-off treatments that tackle a disease at its source, repairing faulty DNA and allowing the body to fix itself.

Colombia's clinical research regulation is friendly to gene therapy trials. Resolución 8430 de 1993 from the Colombian Ministry of Health regulates human research with advanced therapies (including gene therapy). Chapter 1 of the resolution states the following conditions for approval of a gene therapy clinical trial in Colombia.